Levofloxacin Vioser

Levofloxacin, the active ingredient in Levofloxacin Vioser, is a fluoroquinolone antibiotic presented as an intravenous solution for intravenous use. It is indicated for the treatment of serious bacterial infections such as community‑acquired and hospital‑acquired pneumonia, complicated urinary tract infections, intra‑abdominal infections, and skin and soft‑tissue infections in hospitalized adults and, when appropriate, pediatric patients.

GNH USA supplies Levofloxacin Vioser as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory conformity for global healthcare providers.

Levofloxacin Vioser is a fluoroquinolone antibiotic used to treat bacterial infections in various organ systems.

- Community‑acquired pneumonia: eradicates susceptible pathogens and improves clinical recovery. - Hospital‑acquired pneumonia: provides bactericidal activity against resistant strains in severe cases. - Complicated urinary tract infections: eliminates Gram‑negative organisms causing upper‑tract infection. - Complicated intra‑abdominal infections: penetrates peritoneal tissues to treat polymicrobial infections. - Skin and soft‑tissue infections: resolves infections caused by susceptible Staphylococcus and Streptococcus species.

Levofloxacin Vioser may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and often resolves without intervention. - Dizziness: occasional sensation of light‑headedness. - Rash: mild skin erythema or pruritus. - Elevated liver enzymes: transient increase in transaminases.

Serious or Rare Side Effects: - Tendon rupture: especially Achilles tendon, often linked to activity. - QT interval prolongation: risk of ventricular arrhythmias. - Clostridioides difficile infection: severe colitis requiring medical care. - Severe allergic reactions: anaphylaxis, angioedema, or Stevens‑Johnson syndrome. - Hepatic failure: rare but potentially life‑threatening liver injury. - Seizures: particularly in patients with pre‑existing CNS disorders.

Levofloxacin Vioser requires careful patient assessment before use.

- Renal function: adjust dosing in patients with impaired clearance. - QT interval: avoid in individuals with known prolonged QT or on other QT‑prolonging agents. - Hypersensitivity: discontinue immediately if signs of severe allergic reaction appear. - Central nervous system: monitor for seizures, especially in patients with epilepsy or brain disorders. - Tendon health: avoid in patients with tendon disorders or those receiving systemic corticosteroids. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levofloxacin Vioser can interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Theophylline: increased plasma levels can lead to toxicity. - Corticosteroids: combined use raises risk of tendon rupture. - Other QT‑prolonging drugs (e.g., macrolides, antiarrhythmics): additive risk of arrhythmia. - Cyclosporine: may increase levofloxacin concentrations.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce levofloxacin exposure, decreasing efficacy. - Diuretics (especially thiazides): can potentiate hypoglycemia. - Antacids containing aluminum or magnesium: may affect absorption of oral forms, less relevant for IV but monitor overall electrolyte balance. - Antidepressants (e.g., SSRIs): potential for increased QT prolongation, requiring ECG monitoring.